SP/NK-1R系统在乳腺癌中的研究进展

Research progress of SP/NK-1R system in breast cancer

近年来,尽管乳腺癌的治疗已取得诸多进展,但其发病率仍呈上升趋势,寻找新的药物靶点和生物标志物已成为研究热点。越来越多的临床研究开始关注肿瘤细胞与肿瘤微环境的相互作用,认为肿瘤微环境对恶性肿瘤的进展起着至关重要的作用。物质P(Substance P,SP)能够参与癌变过程,在维持肿瘤微环境中发挥着关键作用。NK-1受体(Neurokinin 1 receptor,NK-1R)在肿瘤细胞的细胞质中表达,与诸多肿瘤特征显著相关。SP通过其受体NK-1R诱导肿瘤细胞增殖、血管生成和迁移,并发挥抗凋亡作用。在未来的治疗方案中,能否应用NK-1R拮抗剂为乳腺癌的诊断与治疗提供更精准的靶点成为热点话题。本文就SP/NK-1R系统在乳腺癌中的研究状况进行综述。

In recent years,although many advances have been made in the treatment of breast cancer,its incidence is still on the rise,and the search for new drug targets and biomarkers has become a research hotspot.More and more clinical studies are paying attention to the interaction between tumor cells and tumor microenvironment,and it is believed that tumor microenvironment plays a crucial role in the progression of malignant tumors.Substance P(SP)can participate in the process of carcinogenesis and play a crucial key role in maintaining the tumor microenvironment.Neurokinin 1 receptor(NK-1R)is expressed in the cytoplasm of tumor cells and is significantly associated with many tumor characteristics.SP induces tumor cell proliferation,angiogenesis and migration through its receptor NK-1R,and exerts anti-apoptotic effects.In future treatment plan,whether NK-1R antagonists can be used to provide more accurate targets for the diagnosis and treatment of breast cancer has become a hot topic.This article reviews the research status of SP/NK-1R system in breast cancer.